Navigation Links
Frost & Sullivan Lauds Pioneer Surgical Technology for Development of Tissue Scaffold E-Matrix
Date:3/19/2009

owth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Jake Wengroff
    210.247.3806
    jake.wengroff@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ues increase by 247%, - Net loss reduced signi...rstCall/ - CRH Medical Corporation (CRM:TSX-V) ann...ine months ended September 30, 2009 (all figures a...d September 30, 2009, the Company reported a net l... for the three months ended September 30, 2008, an...
(Date:11/30/2009)...Newswire-FirstCall/ - AIM Health Group Inc. ("AIM"...d health care company, announced today that its ne...r 30, 2009 (the "Quarter") increased to $633,199 f...e time EBITDA(1) increased 290% to $910,734 from $...any also announced that revenues increased 87% to ...
(Date:11/30/2009)...ignificant impact, CBO analysis understates the ef...wire/ -- The Blue Cross and Blue Shield Associat...ng the estimate released today by the Congressiona...ed what many economists, actuaries, and health pol...care reform bill would make coverage more expensiv...
(Date:11/30/2009)... immune cells than sedentary, healthy adults , ,...udies have shown that exercise can help ward off h...s that the reason why may be found within cells th...omeres -- DNA at the tips of chromosomes that prot...althy, nonsmoking adults who did not exercise regu...
(Date:11/30/2009)...Nov. 30 Jedi Mind, Inc ...ased to announce the Company,s first thought-contr... The game, "Think-Tac-Toe" is the first of its kin... power of their mind and is geared towards people ...ce of $49 and can be purchased directly through th...
Breaking Medicine News(10 mins):Health News:CRH Medical reports Q3 2009 results 2Health News:CRH Medical reports Q3 2009 results 3Health News:AIM Health Group Inc. continues increased quarterly profits 2Health News:AIM Health Group Inc. continues increased quarterly profits 3Health News:AIM Health Group Inc. continues increased quarterly profits 4Health News:CBO Confirms That Premiums Will Increase Under the Senate Healthcare Reform Bill 2Health News:Exercise Guards White Blood Cells Against Aging 2Health News:Exercise Guards White Blood Cells Against Aging 3Health News:First Thought-Controlled Game Complete From Jedi Mind, Inc. 2
... coloured, unconventional uniforms makes children ...ding to a study in the April issue of the Journal...versity of Florence, Italy, surveyed a total of 11...an average age of 10, were split into two groups o...
...s on Broader Product Distribution, Revenue Growth ...ecisionView, Inc., the leading provider of Clinica...ustry, today announced that its Board of Directors... Chairman for DecisionView. Scullion succeeds Stev...
...Proceeds Raised in a Follow-on Offering - , , - 1...a Receives Award for Best R&D Lease in ...oning Approved for Redevelopment Project in Cambri...ry - , , PASADENA, Calif., March 31 Alexandr...
...ers Tool to Calculate Your Personal Disability Quo...ard those "one in X people" stats countless times....t something is going to happen to? Now there,s a n...ity Quotient, or PDQ. , , This first-of-its-kind ...
.... (NYSE: CNO ), reported today that it has compl...dit facility. The changes made to the credit agre...he debt to capital ratio through June 30, 2010 to ... A decrease in the minimum risk based capital ...
...ifetime face greatest risk, experts say, , ...e exposure to radiation from CT scans can increase...vard University researchers report. , Widely used ...her radiation dose than most other imaging tests. ...
Other Medicine News:Health News:Multi-colored uniforms improve perceptions of hospital nurses among children and parents 2Health News:DecisionView Board of Directors Appoints James P. Scullion as CEO and President 2Health News:Alexandria Real Estate Equities Provides Update 2Health News:Alexandria Real Estate Equities Provides Update 3Health News:Alexandria Real Estate Equities Provides Update 4Health News:A New Number Everyone Should Know: Their PDQ 2Health News:Conseco Closes Amendment to Credit Facility 2Health News:Conseco Closes Amendment to Credit Facility 3Health News:Conseco Closes Amendment to Credit Facility 4Health News:As CT Radiation Accumulates, Cancer Risk May Rise 2Health News:As CT Radiation Accumulates, Cancer Risk May Rise 3
(Date:11/30/2009)... , NEW YORK, Nov. 30 Repo...report is available in its catalogue: ,, Decub... Review ,, http://www.reportlinker.com/p01642...e-Market-Review.html ,, Decubitus Ulcers are ...stant pressure of the patient,s bodyweight. Pressu...
(Date:11/30/2009)... , KING OF PRUSSIA, Pa., Nov. 30 /PRNewswire/ -...e completion of a Phase I study of CPSI-2364, its ...duction of TNF-alpha and other pro-inflammatory cy...ose escalation study in healthy volunteers confirm...esting. ,, All 30 enrolled subjects completed...
(Date:11/30/2009)..., CHICAGO, Nov. 30 Dr. Jocelyn R...Intervention at George Washington University Medic...cult lesions identified with Breast-Specific Gamma...odality imaging for needle biopsy as well, as for ...ting of the Radiological Society of North America ...
Breaking Medicine Technology:Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 2Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 3Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 4Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 5Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 6Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2Korein Tillery 3A Is Time Running Out for the Manufacturers of the Herbicide Atrazine 3F 55156 1Korein Tillery 3A Is Time Running Out for the Manufacturers of the Herbicide Atrazine 3F 55156 2Korein Tillery 3A Is Time Running Out for the Manufacturers of the Herbicide Atrazine 3F 55156 3Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 55154 1Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 55154 2Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 55154 3NIAID to fund new human immune profiling research centers 55152 1NIAID to fund new human immune profiling research centers 55152 2
...(TM) is evaluating zonisamide SR as a novel compon...EGO, June 07, 2007 /PRNewswire-FirstCall/ -- Orexi...ompany focused on the,treatment of central nervous..., today announced results from a Phase I trial eva...proprietary,sustained-release (SR) formulation of...
...ITY, Calif.--(BUSINESS WIRE)--Jun 6, 2007 - Gilead... Study 102, a,Phase III clinical trial evaluating ...ofovir disoproxil fumarate or tenofovir,DF) 300 mg...virus,(HBV) infection, met its primary efficacy en...r to the company,s once-daily antiviral,drug Hepse...
Other Medicine Technology:OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7
Atria 6100
VASOVIEW® HemoPro™ Endoscopic Vessel Harvesting System
PM-9000 Express Patient Monitor
BC-3200 Auto Hematology Analyzer
Medicine Products: